123 related articles for article (PubMed ID: 29133261)
1. Dual inhibition of BRD4 and PI3K by SF2523 suppresses human prostate cancer cell growth in vitro and in vivo.
Shen G; Jiang M; Pu J
Biochem Biophys Res Commun; 2018 Jan; 495(1):567-573. PubMed ID: 29133261
[TBL] [Abstract][Full Text] [Related]
2. SF2523 inhibits human chondrosarcoma cell growth in vitro and in vivo.
Zhu JX; Xiao JR
Biochem Biophys Res Commun; 2019 Apr; 511(3):559-565. PubMed ID: 30824188
[TBL] [Abstract][Full Text] [Related]
3. Dual inhibition of BRD4 and PI3K-AKT by SF2523 suppresses human renal cell carcinoma cell growth.
Zhu H; Mao JH; Wang Y; Gu DH; Pan XD; Shan Y; Zheng B
Oncotarget; 2017 Nov; 8(58):98471-98481. PubMed ID: 29228703
[TBL] [Abstract][Full Text] [Related]
4. Dual PI3K-BRD4 Inhibitor SF1126 Inhibits Colorectal Cancer Cell Growth in Vitro and in Vivo.
Qin AC; Li Y; Zhou LN; Xing CG; Lu XS
Cell Physiol Biochem; 2019; 52(4):758-768. PubMed ID: 30933440
[TBL] [Abstract][Full Text] [Related]
5. AZD5153 Inhibits Prostate Cancer Cell Growth in Vitro and in Vivo.
Shen G; Chen J; Zhou Y; Wang Z; Ma Z; Xu C; Jiang M
Cell Physiol Biochem; 2018; 50(2):798-809. PubMed ID: 30308485
[TBL] [Abstract][Full Text] [Related]
6. AZD5153, a novel BRD4 inhibitor, suppresses human thyroid carcinoma cell growth in vitro and in vivo.
Xu K; Chen D; Qian D; Zhang S; Zhang Y; Guo S; Ma Z; Wang S
Biochem Biophys Res Commun; 2018 May; 499(3):531-537. PubMed ID: 29596834
[TBL] [Abstract][Full Text] [Related]
7. Bromodomain-Containing Protein 4 (BRD4) Inhibition Sensitizes Palomid 529-Induced Anti-Renal Cell Carcinoma Cell Activity in Vitro and in Vivo.
Xing ZY; Wang Y; Cheng L; Chen J; He XZ; Xing W
Cell Physiol Biochem; 2018; 50(2):640-653. PubMed ID: 30308518
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of BRD4 suppresses tumor growth in prostate cancer via the enhancement of FOXO1 expression.
Tan Y; Wang L; Du Y; Liu X; Chen Z; Weng X; Guo J; Chen H; Wang M; Wang X
Int J Oncol; 2018 Dec; 53(6):2503-2517. PubMed ID: 30272279
[TBL] [Abstract][Full Text] [Related]
9. Induction of autophagy by PI3K/MTOR and PI3K/MTOR/BRD4 inhibitors suppresses HIV-1 replication.
Campbell GR; Bruckman RS; Herns SD; Joshi S; Durden DL; Spector SA
J Biol Chem; 2018 Apr; 293(16):5808-5820. PubMed ID: 29475942
[TBL] [Abstract][Full Text] [Related]
10. Bromodomain protein BRD4 promotes cell proliferation in skin squamous cell carcinoma.
Xiang T; Bai JY; She C; Yu DJ; Zhou XZ; Zhao TL
Cell Signal; 2018 Jan; 42():106-113. PubMed ID: 29050985
[TBL] [Abstract][Full Text] [Related]
11. SF2523: Dual PI3K/BRD4 Inhibitor Blocks Tumor Immunosuppression and Promotes Adaptive Immune Responses in Cancer.
Joshi S; Singh AR; Liu KX; Pham TV; Zulcic M; Skola D; Chun HB; Glass CK; Morales GA; Garlich JR; Durden DL
Mol Cancer Ther; 2019 Jun; 18(6):1036-1044. PubMed ID: 31018997
[TBL] [Abstract][Full Text] [Related]
12. Dual-activity PI3K-BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis.
Andrews FH; Singh AR; Joshi S; Smith CA; Morales GA; Garlich JR; Durden DL; Kutateladze TG
Proc Natl Acad Sci U S A; 2017 Feb; 114(7):E1072-E1080. PubMed ID: 28137841
[No Abstract] [Full Text] [Related]
13. Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy.
Stratikopoulos EE; Dendy M; Szabolcs M; Khaykin AJ; Lefebvre C; Zhou MM; Parsons R
Cancer Cell; 2015 Jun; 27(6):837-51. PubMed ID: 26058079
[TBL] [Abstract][Full Text] [Related]
14. Augmented Antitumor Activity for Novel Dual PI3K/BDR4 Inhibitors, SF2523 and SF1126 in Ewing Sarcoma.
Goldin AN; Singh A; Joshi S; Jamieson C; Durden DL
J Pediatr Hematol Oncol; 2021 Apr; 43(3):e304-e311. PubMed ID: 33480647
[TBL] [Abstract][Full Text] [Related]
15. Oleanolic acid inhibits cell survival and proliferation of prostate cancer cells in vitro and in vivo through the PI3K/Akt pathway.
Li X; Song Y; Zhang P; Zhu H; Chen L; Xiao Y; Xing Y
Tumour Biol; 2016 Jun; 37(6):7599-613. PubMed ID: 26687646
[TBL] [Abstract][Full Text] [Related]
16. Targeting PI3K-AKT-mTOR by LY3023414 inhibits human skin squamous cell carcinoma cell growth in vitro and in vivo.
Zou Y; Ge M; Wang X
Biochem Biophys Res Commun; 2017 Aug; 490(2):385-392. PubMed ID: 28623128
[TBL] [Abstract][Full Text] [Related]
17. Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation.
Ghosh PM; Malik SN; Bedolla RG; Wang Y; Mikhailova M; Prihoda TJ; Troyer DA; Kreisberg JI
Endocr Relat Cancer; 2005 Mar; 12(1):119-34. PubMed ID: 15788644
[TBL] [Abstract][Full Text] [Related]
18. Targeting BRD4 and PI3K signaling pathways for the treatment of medulloblastoma.
Sethi B; Kumar V; Jayasinghe TD; Dong Y; Ronning DR; Zhong HA; Coulter DW; Mahato RI
J Control Release; 2023 Feb; 354():80-90. PubMed ID: 36599397
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3'-kinase pathway.
Miyake H; Nelson C; Rennie PS; Gleave ME
Endocrinology; 2000 Jun; 141(6):2257-65. PubMed ID: 10830316
[TBL] [Abstract][Full Text] [Related]
20. Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells.
Pfeil K; Eder IE; Putz T; Ramoner R; Culig Z; Ueberall F; Bartsch G; Klocker H
Prostate; 2004 Feb; 58(3):259-68. PubMed ID: 14743465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
